Dynavax Technologies Corporation - Common Stock (DVAX)
13.05
+0.04 (0.31%)
Dynavax Technologies is a biotechnology company focused on developing innovative immunotherapies to treat and prevent infectious diseases and cancer
Its research emphasizes harnessing the body's immune system to generate strong and durable responses, particularly through the use of its proprietary toll-like receptor (TLR) technology. The company is known for its commitment to advancing novel vaccine approaches and immune-modulating therapies, with a portfolio that includes products aimed at improving patient outcomes and enhancing immune response in various therapeutic areas. Dynavax collaborates with other organizations to drive advancements in biomedical research and bring transformative solutions to healthcare.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors’ and officers’ possible violations of state laws.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQLNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus’ Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board’s Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.
Shares of RxSight, Inc. (NASDAQRXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
